临床进展中的BDK抑制剂

IF 6.8 1区医学 Q1 CHEMISTRY, MEDICINAL

Journal of Medicinal Chemistry Pub Date : 2025-01-15 DOI:10.1021/acs.jmedchem.5c0000210.1021/acs.jmedchem.5c00002

Kukkamudi Sreenivas, and , Chintada Nageswara Rao*,

引用次数: 0

摘要

心脏及相关疾病的生理病理与BCAA代谢失衡密切相关。BDK是BCKDH复合物的负调节因子，在BCAA分解代谢功能障碍中起重要作用。一种具有临床潜力的BDK抑制剂PF-07328948，具有优异的药物样特性，正在进行CVD代谢紊乱的i期临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Clinically Advancing BDK Inhibitors

The physiopathology of cardiac and related disorders is strongly associated with BCAA metabolic imbalance. BDK, a negative regulator of the BCKDH complex, is significant in BCAA catabolic dysfunction. A Clinically potential BDK inhibitor, PF-07328948, with excellent drug-like properties, is under phase-1 clinical trials for CVD metabolic disorders.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Medicinal Chemistry 医学-医药化学

CiteScore

4.00

自引率

11.00%

发文量

804

审稿时长

1.9 months

期刊介绍： The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.